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Background: As part of its policy to shift monitoring of
antiretroviral therapy (ART) to primary health care (PHC) workers,
the Ministry of Health of the Democratic Republic of Congo (DRC)
tested the feasibility of using dried blood spots (DBS) for viral load
(VL) quantiﬁcation and genotypic drug resistance testing in off-site
high-throughput laboratories.
Methods: DBS samples from adults on ART were collected in 13
decentralized PHC facilities in the Nord-Kivu province and shipped
during program quarterly supervision to a reference laboratory 2000 km
away, where VL was quantiﬁed with a commercial assay (m2000rt,
Abbott). A second DBS was sent to a World Health Organization
(WHO)-accredited laboratory for repeat VL quantiﬁcation on a subset of
samples with a generic assay (Biocentric) and genotypic drug resistance
testing when VL .1000 copies per milliliter.
Findings: Constraints arose because of an interruption in national
laboratory funding rather than to technical or logistic problems. All
samples were assessed by both VL assays to allow ART adjustment.
Median DBS turnaround time was 37 days (interquartile range:
9–59). Assays performed unequally with DBS, impacting clinical
decisions, quality assurance, and overall cost-effectiveness. Based on
m2000rt or generic assay, 31.3% of patients were on virological
failure (VF) and 14.8% presented resistance mutations versus 50.3%
and 15.4%, respectively.
Conclusion: This study conﬁrms that current technologies involv-
ing DBS make virological monitoring of ART possible at PHC level,
including in challenging environments, provided organizational
issues are addressed. Adequate core funding of HIV laboratories
and adapted choice of VL assays require urgent attention to control
resistance to ART as coverage expands.
Key Words: HIV, ART monitoring, Democratic Republic of Congo,
dried blood spots, viral load assay, programmatic context
(J Acquir Immune Deﬁc Syndr 2016;71:e9–e15)
INTRODUCTION
Between 2006 and 2012, the Ministry of Health of the
Democratic Republic of the Congo (DRC) and the Inter-
national Union Against Tuberculosis and Lung Disease
(The Union) piloted the program “Integrated HIV Care for
Tuberculosis Patients Living with HIV/AIDS” (IHC) in
health facilities that successfully implement the national
tuberculosis program, as a contribution to expanding HIV
care coverage. IHC followed WHO recommendation for
antiretroviral therapy (ART). The National Health Policy of
DRC stresses the systemic challenge posed by the imbal-
ance introduced by funding related to the sixth Millennium
Development Goal in the national health account, making
the search for efﬁciency a priority. In response to the
shortage of human resources in the health sector, patient
follow-up was delegated to primary health care nurses
supported by quarterly medical supervision after The
Union’s approach.1 Shifting ART monitoring to nurses
requires robust criteria for diagnosing treatment failure.2
As on-site CD4 counts posed serious logistic and mainte-
nance challenges, we piloted the introduction of virological
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monitoring before the publication of the 2013 WHO
recommendations for monitoring ART.3
The estimated HIV prevalence of 1%–1.2%4 and weak
laboratory infrastructure in DRC may not justify an extensive
decentralization of technology for viral load (VL) testing.
Dried blood spots (DBS) have proven a suitable matrix for
both VL quantiﬁcation and genotypic drug resistance testing.5
DBS can be safely shipped6 to laboratory hubs where testing
can be sustained, and test throughput and deployment of
adequately qualiﬁed laboratory personnel optimized.7
We previously validated that DBS can be stored up to 4
weeks at ambient temperature (20°C) then kept frozen until
RNA is quantiﬁed or genotypic drug resistance tested.8 We
also previously optimized storage and RNA extraction meth-
ods.9 To test the operational feasibility of VL monitoring under
program conditions, we conducted our study in the 3 district
hospitals and 10 health centers that participated in IHC in the
Nord-Kivu province, 2000 km east of Kinshasa (DRC). These
units provide a close approximation of the proﬁle of ﬁrst level
health facilities in the country likely to provide HIV care on
a regular basis, and therefore to monitor ART effectiveness. On
average, 13% of tuberculosis patients and 1% of antenatal
clinic attendants in these health facilities were HIV-positive,
and more than 90% of patients on ART were alive at 48 months
follow-up (IHC statistics, 2012). To test our programmatic
implementation, we collected DBS samples in those peripheral
care facilities and shipped them to central laboratory hubs for
VL and genotypic resistance testing.
METHODS
We applied WHO-recommended health technology
assessment parameters,10 adapted the criteria speciﬁc to assess-
ing HIV monitoring equipment in resource-constrained settings
proposed by Stevens et al,11 and included the dimension of
equity.12 Table 1 presents the set of criteria applied. The study
was authorized by the ethics advisory boards of the School of
Public Health, Kinshasa, and The Union and implemented as
part of regular national program operation.
VL Hubs
AVL hub was established at the National AIDS Reference
Laboratory in Kinshasa (LNRS), and a second hub for repeat VL
quantiﬁcation and genotyping at the Institut pour la Recherche et
le Développement, Montpellier, France (UMI233), a WHO-
accredited laboratory for HIV drug resistance testing on DBS.
Before the study, UMI233 assessed the LNRS based on the
qualitative parameters presented in Table 1. UMI233 also
provided LNRS with technical support and external quality
assurance. Routine operation of the LNRS was ﬁnanced with
a Global Fund grant to the National AIDS Program.
Study Sites and Patient Samples
Before patient enrollment, the regional TB-AIDS
physician-supervisor trained laboratory technicians in han-
dling DBS in 3 district hospitals and 10 health centers that
participated at the IHC in the Nord-Kivu province. Between
April 2011 and August 2012, 188 HIV-positive consenting
adults treated with ART for at least 12 months in Nord-Kivu
facilities were consecutively enrolled in the study. All patients
reported no previous ART exposure; they were treated with
the national ﬁrst-line regime (stavudine/zidovudine, lamivu-
dine, nevirapine/efavirenz). At patient enrollment, DBS (5
spots of 50 mL of whole blood) were prepared on Whatman
Protein Saver 903 paper (GE-Healthcare, Pittsburgh, PA),
dried at ambient temperature (20–28°C) for a minimum of 3
hours, placed in a zip-lock plastic bag with Minipax desiccant
packs (Multisorb Technologies, Buffalo, NY) and a humidity
TABLE 1. Qualitative Parameters for the Evaluation of the Tiered Laboratory Approach Using DBS to Centralize Samples in High-
Throughput Laboratory Hubs
Appropriateness Effectiveness Efﬁciency
Context-related
parameters
 Patients’ geographic and ﬁnancial accessibility  Required turnaround time of test  Epidemiology
 Sample logistics
Hub-related
parameters
 Laboratory infrastructure available  Available external quality
assessment
 Anticipated daily volume of samples
 Available transport from site to hub  Costs of operating infrastructure (operation
and maintenance)
 Local available expert reference  Availability of sustainable funding
mechanisms
 Available staff skills
 Proﬁciency of laboratory processes
Method-related
parameters
 Sample transport requirements  Stability of samples  Equipment requirements
 Additional energy and temperature
requirements
 System performance in context  Single/multiple tests
 Workﬂow analysis  Stafﬁng requirements
 Supplier and/or vendor availability for support
and maintenance
 Cost of equipment and reagents
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indicator, and stored at 212°C in the freezer compartment of
the facility fridge, after permission was obtained from the
vaccination program that uses that space for its cool packs.
Two DBS cards were prepared for each patient. DBS were
collected at the next quarterly supervision round with
anonymized test requests, shipped by courier to LNRS, then
stored at 280°C until processed. One DBS card was
subsequently shipped to UMI233 laboratory.
HIV VL Quantification
Both laboratories applied routine methods according
to manufacturer’s recommendations to quantify VL:
UMI233 used the G2 generic real-time polymerase chain
reaction assay (Biocentric, Bandol, France) to quality-
assure LNRS results obtained with the m2000rt Real-
Time HIV-1 assay (Abbott, Chicago, IL). The intrinsic
characteristics and limits of detection of these assays were
previously reviewed13 and found to be compatible with the
thresholds we used in this study; they are not yet listed for
use with DBS in DR Congo. Nucleic acids were recovered
from DBS by incubation of 2 spots (total 100 mL) in 1.7 mL
(m2000rt) or in 2 mL (G2 generic) of lysis buffer for
30 minutes under shaking. Paper particles were eliminated
from recovered eluate by centrifugation. Clear supernatants
were used for RNA extraction. For VL quantiﬁcation
with the G2 generic assay, the Qiagen extraction kit
recommended for plasma samples was substituted by the
NucliSens miniMag extraction system (BioMérieux, Cra-
ponne, France) because of Qiagen kit’s low performance
with DBS.9
VL results were returned by e-mail to the health
facilities. Clinical decisions documented in patients’ records
were supervised at the next round. Constraints encountered
during implementation were reported in supervision reports.
Turnaround time was measured between DBS sampling and
return of the result.
Genotyping Drug Resistance Testing
To ascertain the proportion of failures due to drug
resistance, DBS from patients with VL $ 1000 copies per
milliliter were tested at the UMI233 for drug resistance
mutations (DRM). Nucleic acids were extracted using the
Nuclisens miniMag method as described previously. Geno-
typing in the reverse transcriptase gene region followed the
ANRS in-house protocol (www.hivfrenchresistance.org/
ANRS-procedures.pdf). Polymerase chain reaction products
were directly sequenced using the BigDye Terminator v3.1
Cycle Sequencing kit (Applied Biosystems, Carlsbad, CA).
All sequences were checked for quality assurance using the
calibration population resistance sequence quality analysis
tool (http://cpr.stanford.edu) before further analyses. The
ANRS interpretation algorithm (www.hivfrenchresistance.
org/2014/Algo-2014.pdf) was used to identify DRM and to
predict antiretroviral drug resistance to the drugs of the
current ﬁrst-line ART. The full list of mutations for all
genotyped samples along with the VL results from
each assay, HIV-1 subtypes, and drug treatment details
(ART regimen and duration) is presented as Supplemental
Digital Content 1, http://links.lww.com/QAI/A751.
Nucleotide Sequences Accession Numbers
and List of Mutations
All newly HIV-1 sequences have been deposited in the
Genbank Nucleotide Sequence database under accession
numbers KT315948-KT316002.
Data Analysis
We represented VL results above 1000 copies per
milliliter obtained with both m2000rt and the G2 generic
assays with linearity plot (expressed in log10-transformed
copies/mL). Correlation between assays was measured by
a Pearson correlation test. Then, for bias and agreement
measurements, we analyzed VL values using the Bland–
Altman approach14 at both 1000 and 5000 copies per
milliliter VL thresholds. The Bland–Altman graph plots
the difference between individual VL values from both
techniques against the mean.
RESULTS
Implementation and Patient Characteristics
Of 188 patients enrolled in the study, 11 (5.8%) did not
fulﬁll all the inclusion criteria and were excluded. Of the
remaining 177 patients, women predominated (N = 119, 67%).
The median age was 40 years [interquartile range (IQR):
35–46]. The median duration on ART was 29 months (IQR:
19–44). No particular difﬁculty related to DBS preparation or
shipping was reported. The median time between collection of
the samples and reception at the LNRS was 37 days (IQR:
9–59). All samples were suitable for extraction.
Samples shipped to UMI233 in Montpellier were
analyzed on reception. The LNRS in Kinshasa stopped VL
analyses when the Global Fund temporarily suspended grant
disbursements in 2011. Stored DBS samples could only be
analyzed in February 2013 after the m2000rt system had been
recalibrated.
VL Quantification
VLs below 1000 copies per milliliter were reported for
124/177 (70.1%) samples analyzed with the m2000rt assay
and for 92/177 (51.4%) samples analyzed with the G2 generic
assay. No HIV was detected with the G2 generic assay in 30
of these samples. As G2 generic technique also detects
proviral DNA, this warranted complementary assessment of
these patients’ HIV status, and they were retested with INNO-
LIA HIV-I/II Score (Fujirebio Europe, Gent, Belgium) for the
presence of HIV antibodies. Eight (4.5%) patients were
conﬁrmed HIV-negative and were excluded from the study.
We found a positive correlation between paired VL
results (expressed in log10 copies/mL) with a coefﬁcient of
determination r2 of 0.772 (Pearson test, P , 0.0001), taking
into account only samples with VL reported as .1000 copies
per milliliter with both assays (N = 48) (Fig. 1). Bland–Altman
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analyses (Fig. 2) indicated a better correlation and agreement at
the 5000 copies per milliliter threshold and returned a mean
difference between VL measures of 0.53 log.
The concordance of detecting virological failure (VF)
between the 2 systems was 75.1% (127/169, Kappa coefﬁcient:
0.50) at the 1000 copies per milliliter threshold and 89.9%
(152/169, Kappa coefﬁcient: 0.72) at 5000 copies per milliliter
(Table 2). The concordance between the 2 systems decreased
to 69.2% (117/169, Kappa coefﬁcient: 0.47) when VL samples
were classiﬁed in ,1000, 1000–4999, and $5000 copies per
milliliter categories. This lowest concordance was essentially
due to the 47 samples (27.8%) that were classiﬁed in the 1000–
4999 copies per milliliter category by the G2 generic system
compared with only 12 (7.1%) by the m2000rt assay.
Genotypic Drug Resistance Testing
At the VF threshold of 1000 copies per milliliter,
genotyping was successful for 75.5% and 62.4% of samples
analyzed with the m2000rt and the G2 generic systems,
respectively (Table 3). When the m2000rt assay was used,
DRM were identiﬁed in 25 samples, resulting in a minimum (as
we could not genotype all samples) of 47.2% of patients with
VF harboring resistance mutations, and 14.8% of drug resistance
prevalence in patients on ART. With the G2 generic system, 26
samples with DRM were identiﬁed, resulting in a minimum of
30.6% of patients with VF harboring resistance mutations, and
15.4% of drug resistance prevalence in patients on ART. At the
VF threshold of 5000 copies per milliliter, genotyping was
successful for 82.9% and 78.9% of analyzed samples, and drug
resistance was found in 24 (14.2%) and 18 (10.6%) samples
with the m2000rt and G2 generic systems, respectively.
Using the criterion of a VF threshold at 1000 copies per
milliliter for both VL quantiﬁcation assays, a total of 90 DBS
were tested for DRM by genotyping (Table 3). Among those
patients, 55 were successfully genotyped and mutations
associated with drug resistance were observed in 27 of them.
Resistance mutations were found in 2 patients (patient ID
VIR29 and MAN02) with VL below 1000 copies per
milliliter with the m2000rt system but above 1000 copies
per milliliter with the G2 generic system, and in 1 patient
(patient ID MAB06) with VL below 1000 copies per milliliter
with the G2 generic system but above 5000 copies per
milliliter with the m2000rt system (Table, Supplemental
Digital Content 1, http://links.lww.com/QAI/A751). At
a threshold of 1000 copies per milliliter, the m2000rt and
the G2 generic assays detected very similar percentage of
resistance mutations [92.6% (25/27) and 96.3% (26/27),
respectively], but the G2 generic assay involved a higher
numbers of VF samples selected for genotyping resistance,
85/169 (48%) compared with 53/169 (31.3%) with the
m2000rt assay. At a threshold of 5000 copies per milliliter,
the m2000rt system detected 24/27 (88.9%) of resistant
strains and the G2 generic system 18/27 (66.7%).
Drug Resistance Analysis
Details of the 55 characterized patients are given as
supplemental data content (Table, Supplemental Data Content
1, http://links.lww.com/QAI/A751 which presents our ﬁnd-
ings on DRM). Among resistance mutations for nucleoside
reverse transcriptase inhibitors, M184V was most common
and was found in 21/27 resistant patients (78%). Among
resistance mutations for nonnucleoside reverse transcriptase
FIGURE 1. Correlation between paired VL measurements
obtained with the m2000rt (Abbott, Chicago, IL) and G2
generic (Biocentric, Bandol, France) assays for samples with VL
above 1000 copies per milliliter (N = 48). The solid line rep-
resents the fitted regression. Pearson coefficient of determi-
nation r2 = 0.772, P , 0.0001.
FIGURE 2. Bland–Altman plots of
agreement between VLs quantified
using the m2000rt (Abbott, Chicago,
IL) and G2 generic (Biocentric, Ban-
dol, France) assays at a threshold of
1000 copies per milliliter (A) (N = 48)
and 5000 copies per milliliter (B) (N =
31). The solid red line represents the
mean bias on the difference. The gray
lines represent the limits of agreement
(Sup limit = mean difference + 2
standard deviations; Inf limit = mean
difference 2 2 SDs).
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inhibitors, K103N was most frequent and was detected in 18/
27 resistant patients (67%). All others mutations were found
in 9 or less patients.
On-Site Patient Follow-up
VL results were returned to the TB-AIDS supervisor
with the recommendation to review adherence of all patients
with VL $ 1000 copies per milliliter. As the G2 generic
results were available ﬁrst, this effort was required for 32
more patients (160%) than would have been required on the
basis of results obtained with the m2000rt system. As
genotypic resistance results became available, the 27 patients
with VF due to drug resistance were prescribed second line
ART, after possible adherence issues were addressed.
The 8 HIV-negative patients were informed of the new
ﬁnding and ART was discontinued, albeit with difﬁculty to
explain that the initial AIDS diagnostic was actually errone-
ous and the months of ART unnecessary.
DISCUSSION
Equitable access to health technology is critical for
universal health coverage.15 Despite renewed interest in health
system issues and growing attention by global funding
mechanisms,16 health technology assessments remain little
used in the global health context. The concept of using DBS
for centralizing VL samples at reference laboratories in
resource-constrained environments has been proven for some
years,5,7–9,17 but our review of the PubMed and Google
Scholar databases found no report of its successful roll-out
under programmatic conditions. Its application to the DRC
context and appropriation by the management of the National
AIDS Control Program demonstrated its feasibility under
particularly challenging programmatic conditions. By doing
so, it balanced technology challenges with systemic chal-
lenges of equal importance.
The approach based on currently available technol-
ogy permits to decentralize VL measurement to all types of
peripheral health facilities where ART is prescribed. By
centralizing technology where it can be sustained, and
standardizing monitoring procedures, it also reduces the
technical complexity of ART monitoring.18 It requires
minimal additional resources at care level and is supported
by the integrated delivery of tuberculosis and HIV care in
a primary health care setting. Quarterly supervision is
essential for the logistical component of this approach but
would in any case be a condition for ART task-shifting.
Centralizing VL measurements in laboratory hubs signiﬁ-
cantly reduces the cost and complexity of the laboratory
supply chain and the requirements for highly trained
laboratory personnel. The effectiveness of such hubs will
rest not only on a capacity to operate and sustain the test
but also on the conjunction of this capacity with the
supervision circuit. A similar nodal approach guided
the development of the Basic Management Unit to which
the so-called Directly Observed Treatment Short course
strategy for tuberculosis control of the WHO owes part of
its success1 (several peripheral health facilities share
laboratory equipment in the facility where proﬁciency can
be secured).
The interruption of services at the LNRS in Kinshasa
during the study was due to a ﬁnancing bottleneck rather than
to technology constraints, recalling attention to a critical
weakness in the ﬁnancing of laboratory systems in Africa.19
When the ﬁnancing constraints of laboratory hubs are
TABLE 2. VF* Based on VL at the 1000 and 5000 copies per
milliliter Thresholds
VL Assay†,
G2 Generic
m2000rt
VL‡ , 1000
m2000rt
VL ‡ 1000 Total
VL , 1000 79 5 84 (49.7%)
VL $ 1000 37 48 85 (50.3%)
Total 116 (68.8%) 53 (31.4%) 169
VL Assay,
G2 Generic
m2000rt
VL , 5000
m2000rt
VL ‡ 5000 Total
VL , 5000 121 10 131 (77.5%)
VL $ 5000 7 31 38 (22.5%)
Total 128 (75.7%) 41 (24.3%) 169
*VF is deﬁned as a VL $ deﬁned threshold (expressed in copies/mL).
†Methods used for VL quantiﬁcation.
‡VL expressed in copies per milliliter.
TABLE 3. VF* and Genotypic Resistance to Antiretroviral Treatment Prevalence
VL Assay†
Threshold
(copies/mL) VF* Samples
VF Samples Successfully
Genotyped
VF Samples With RTI‡
Resistance Mutations
Prevalence of Resistance
(Estimated Minimum)
m2000rt 1000 53/169 (31.3) 40/53 (75.5%) 25/53 (47.2%) 25/169 (14.8%)
G2 generic 1000 85/169 (50.3%) 53/85 (62.4%) 26/85 (30.6%) 26/169 (15.4%)
Both tests
combined
1000 90/169 (53.3%) 55/90 (61.1%) 27/90 (30.0%) 27/169 (16.0%)
m2000rt 5000 41/169 (24.3%) 34/41 (82.9%) 24/41 (58.5%) 24/169 (14.2%)
G2 generic 5000 38/169 (22.5%) 30/38 (78.9%) 18/38 (47.4%) 18/169 (10.6%)
Both tests
combined
5000 48/169 (28.4%) 39/48 (81.3%) 24/48 (50.0%) 24/169 (14.2%)
*VF is deﬁned as a VL $ deﬁned threshold (expressed in copies/mL).
†Methods used for VL quantiﬁcation.
‡RTI, reverse transcriptase inhibitors including nucleoside and nonnucleoside inhibitors.
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effectively addressed, reliable information on the VL of
patients on ART can be returned to peripheral clinics within
an acceptable period. A 37-day median turnaround time may
seem long, but in the context of chronic care with monthly
consultations, and a decision-making process that involves
a comprehensive adherence review that spans over weeks, it
remains compatible with sound clinical practice.
Our results highlight the intrinsic variability between
different types of VL assays20 and conﬁrm that they are not
equally suitable for testing DBS samples.21 Trained labo-
ratory technicians can operate the m2000rt and the G2
generic systems equally well, but the G2 generic system
requires more supervision and more experienced techni-
cians. Savings from generic technology are also discounted
by the current need for a different extraction kit for DBS.
Furthermore, using the G2 generic assay at the 1000 copies
per milliliter VF threshold (after the new 2013 WHO
recommendations for monitoring ART3) would have
imposed unnecessary efforts of reviewing adherence for
19% of our cohort and their care providers and an increased
cost related to additional genotypic drug resistance testing,
whereas at the 5000 copies per milliliter threshold, 25% of
resistant strains would have been missed. Finally, our
results also suggest that external quality assurance of VL
quantiﬁcation should be implemented using the same
technology as used for initial quantiﬁcation.17
The 4.5% false-positive diagnoses for HIV infection
in our cohort are consistent with the 5%–10% range
reported in Central Africa.22–24 This raises concerns about
iatrogenesis and costs of treatment programs, and stresses
a need to strengthen the quality assurance of HIV diagnosis.
Beyond monitoring ART effectiveness, DBS provide
a wider base for efﬁciencies that cost-effectiveness analyses
should consider: Extended DBS sampling permits early
infant diagnosis of HIV infection7 and facilitates quality
assurance for patients diagnosed with HIV.25 Banked DBS
provide a highly representative sampling base for
monitoring HIV resistance not only in terms of geographic
origin or care facility level but also as they allow
comparison between VL suppression—a WHO Early
Warning Indicator,26 and resistance, in the same patients.
This would avoid costly ad hoc surveys and greatly
facilitate the implementation of WHO recommendations
on resistance surveillance.27
Current warnings about the high cost and low cost-
effectiveness of VL monitoring28,29 may therefore be pre-
mature. Similar concerns about the introduction of ART
a decade ago30,31 reminds us that decision to introduce
a costly strategy with controversial cost-effectiveness
primarily rests on political motivation. When the high
laboratory costs of VL monitoring are offset by savings
generated by increased efﬁciencies of laboratory systems,
we may be closer than expected toward the hypothesis of
the modeling study by Keebler et al32 “If the cost of VL
monitoring falls, it might become a cost-effective strategy
in the future, particularly in settings with high ART
coverage.” The announcement by UNAIDS of a price per
VL test below 10 US$ indicates that the future mentioned
by Keebler is happening.33
CONCLUSION
We conﬁrmed under regular program operation that the
combination of DBS sampling and laboratory hubs for VL
quantiﬁcation provides the technology that currently allows
for equitable and efﬁcient monitoring of ART delivered at the
primary care level in a resource-constrained environment.
Although further studies are required to assess the impact of
this approach on the roll-out of VL monitoring, it is critical
that efforts in improving technologies be balanced with the
search of solutions to sustain the funding of HIV laboratories.
The high level of ART resistance observed among the study
population draws attention to the urgent need to better
understand the effectiveness of current ART regimes, as the
services to deliver them are expanded and decentralized.
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